Surgery Websites
Robotic Surgery »  Meet the Team »  Surgical Faculty »  Tobias Deuse, M.D.
Tobias Deuse, M.D.

Tobias Deuse, M.D.

  • Professor of Surgery
  • Division of Adult Cardiothoracic Surgery
  • The Julien I.E. Hoffman, M.D. Endowed Chair in Cardiac Surgery
  • Director, Minimally-invasive Cardiac Surgery
  • Surgical Director, Transcatheter Valve Program

Contact Information

Academic Office:
500 Parnassus Ave, MUW 405, Box 0118
San Francisco, CA 94143
Tel: (415) 353-8196
Email: [email protected]
Admin: [email protected] 
Cardiac Surgery Program
400 Parnassus Avenue, Suite 501, Box 0118
San Francisco, California,  94143
Fax: 415-353-1312
Lung Transplant Program
400 Parnassus Ave., 6/F, Box 0115
San Francisco, CA 94143
Tel: 415-353-4145
Fax: 415-353-4166
Heart Transplant Program
400 Parnassus Avenue, Suite 501, Box 0115
San Francisco, CA 94143
Fax: 415-502-0243

Open Popup

University of Stuttgart (Germany), BS, Physics, 1994

University of Leipzig (Germany) Medical School, 1995

Julius-Maximilian-University Würzburg (Germany) Medical School, MD, 2000

Ludwig-Maximilian-University Munich (Germany) Medical School, 2001

  • University Hospital Munich-Grosshadern (Germany), Cardiac Surgery, 2001
  • University Heart Center Hamburg-Eppendorf (Germany), Cardiovascular Surgery, 2002-2007
  • Stanford University, Lung and Heart-Lung Transplantation, Fellowship Program, 2007-2009
  • UCSF Heart & Vascular Center
  • Acute Aortic Dissection Repair
  • Aortic Valve Repair & Replacement
  • Arrhythmia
  • Coronary Artery Bypass Grafting (CABG)
  • Heart Transplantation
  • Lung Transplantation
  • Minimally Invasive Aortic Valve Surgery
  • Minimally Invasive Atrial Septal Defect (ASD) Closure
  • Minimally Invasive Mitral Valve Surgery
  • Off-Pump Coronary Artery Bypass (OPCAB)
  • Ventricular Aneurysm
  • Ventricular Assist Devices (VAD)
  • Oxidative Stress and Apoptosis
  • Pulmonary Hypertension
  • Stem Cell Immunobiology
  • Transplant Immunology
  • Vascular Biology
  • German

Tobias Deuse, M.D. is a cardiac and heart transplant surgeon internationally renowned for his pioneering work in the development of minimally-invasive techniques for mitral valve repair. 

Dr. Deuse graduated the University of Stuttgart (Germany) in 1994 with a BS in Physics, and in 2000 earned an M.D. from University of Wuerzburg. Dr. Deuse thereafter received advanced training in cardiothoracic surgery at the University Hospital Munich-Grosshadern and University Heart Center Hamburg-Eppendorf. After obtaining his board certification in Germany in 2007 as a heart surgeon, Dr. Deuse completed a surgical fellowship in Lung and Heart-Lung Transplantation at Stanford.

After returning to Germany in 2009, Dr. Deuse was appointed Director for Heart and Lung Transplantation at the University Heart Center in Hamburg. He achieved international acclaim for his development of innovative approaches to heart failure surgery, most notably minimally-invasive techniques for the implantation of ventricular assist systems. 

Dr. Deuse also demonstrated that high success rates could be achieved in mitral valve repair utilizing robotic-assisted (fully) endoscopic surgery. This minimally invasive procedure, also known as "keyhole surgery", has numerous benefits for the patient including substantially reduced post-surgical pain, shorter hospital stays, and a faster recovery and return to normal activities. 

Dr. Deuse has also been the recipient of numerous honors including election to the Board of Directors of the International Society for Heart and Lung Transplantation (ISHLT).

Dr. Deuse's research is focused on vascular biology and pathophysiology. His group was the among the first to elucdiate the novel pathways involved in the development of vascular intimal hyperplasia. Myointimal hyperplasia is a pathological process of the vascular system characterized by abnormal proliferation of smooth muscle cells of the vascular wall that leads to luminal obliteration and subsequent ischemia.

Myointimal hyperplasia may occur in patients after vessel injury during medical procedures (e.g. after balloon dilation or stent placement) or after pathological injury of the blood vessel (e.g. due to inflammation or toxic exposure). It can cause bypass graft failure and in-stent restenosis. To help prevent this and increase the success of treatments for vascular disease including coronary heart disease, his research group is working on the development of new preventive drug regimes and strategies.

Data provided by UCSF Profiles, powered by CTSI
  • Hypo-immunogenic cardiomyocytes for myocardial repair
    Sponsor ID:
    Funding Period:
    Aug 2018
    Jun 2022
    Principal Investigator
  • Microgravity as model for immunological senescence and its impact on tissue stem cells and regeneration
    Sponsor ID:
    Funding Period:
    Jun 2017
    Jun 2021
    Co-Principal Investigator
Data provided by UCSF Profiles, powered by CTSI
  1. Gravina A, Tediashvili G, Zheng Y, Iwabuchi KA, Peyrot SM, Roodsari SZ, Gargiulo L, Kaneko S, Osawa M, Schrepfer S, Deuse T. Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity. Cell Stem Cell. 2023 Nov 02; 30(11):1538-1548.e4. View in PubMed
  2. Hu X, White K, Olroyd AG, DeJesus R, Dominguez AA, Dowdle WE, Friera AM, Young C, Wells F, Chu EY, Ito CE, Krishnapura H, Jain S, Ankala R, McGill TJ, Lin A, Egenberger K, Gagnon A, Michael Rukstalis J, Hogrebe NJ, Gattis C, Basco R, Millman JR, Kievit P, Davis MM, Lanier LL, Connolly AJ, Deuse T, Schrepfer S. Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques. Nat Biotechnol. 2023 May 08. View in PubMed
  3. Hu X, Gattis C, Olroyd AG, Friera AM, White K, Young C, Basco R, Lamba M, Wells F, Ankala R, Dowdle WE, Lin A, Egenberger K, Rukstalis JM, Millman JR, Connolly AJ, Deuse T, Schrepfer S. Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice. Sci Transl Med. 2023 04 12; 15(691):eadg5794. View in PubMed
  4. Hu X, Manner K, DeJesus R, White K, Gattis C, Ngo P, Bandoro C, Tham E, Chu EY, Young C, Wells F, Basco R, Friera A, Kangeyan D, Beauchesne P, Dowdle WE, Deuse T, Fry TJ, Foster AE, Schrepfer S. Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice. Nat Commun. 2023 04 10; 14(1):2020. View in PubMed
  5. Gravina A, Tediashvili G, Rajalingam R, Quandt Z, Deisenroth C, Schrepfer S, Deuse T. Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression. Nat Biotechnol. 2023 05; 41(5):717-727. View in PubMed
  6. View All Publications


Site Directory